ASAndrew C. Stokes

Andrew C. Stokes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew C. Stokes has a total of 438 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment

    by Minh Trung Le, Andrew C Stokes

    Introduction: Semaglutide and tirzepatide, the 2 most recently approved glucagon-like peptide-1 receptor agonists, have demonstrated substantial effectiveness in weight management. However, evidence on treatment inequities remains limited. This study assesses temporal trends and sociodemographic disparities in semaglutide and tirzepatide prescription. Methods: Using claims data from Komodo Health, we identified commercially insured individuals aged 18–64 years with overweight or obesity but without type 2 diabetes. We estimated 6-month cumulative incidence of semaglutide and tirzepatide prescription across sociodemographic groups and examined disparities by health care provider socioeconomic status. Results: Six-month cumulative incidence of prescription increased from 1.9% to 16.6% over the study period. Higher access was associated with being female, non-Hispanic White, in higher body mass index categories, and seen at a higher socioeconomic status (SES)–quartile provider. Uptake was significantly lower in lower provider neighborhood SES groups (lowest quartile adjusted odds ratio: 0.75; 95% CI: 0.73–0.78, compared with the highest quartile), and the differences widened over time. The SES disparities were more pronounced at lower BMI categories. Conclusion: Prescription of semaglutide and tirzepatide increased rapidly from 2021 to 2025. Sociodemographic disparities widened over time. Policies addressing provider-level resourcing and pharmaco-equity in drug benefit design are needed to prevent these therapies from exacerbating existing health disparities.

  • Open Access

    Prevalence and Patterns of E-Cigarette Use Among U.S. Adults: A Repeated Cross-Sectional Analysis of the All of Us Research Program, 2017–2023

    by John Erhabor, Zhiqi Yao, Erfan Tasdighi, Omar El-Shahawy, Emelia J. Benjamin, Aruni Bhatnagar, Andrew Stokes, Michael Joseph Blaha

    Introduction: Large-scale, ongoing cohort studies may offer a complementary approach for monitoring population patterns of e-cigarette use alongside established national surveillance systems. This study assessed the prevalence and patterns of current and daily e-cigarette use among adults in the All of Us Research Program from 2017 to 2023 and compared observed patterns with those from established national surveys. Material and methods: This repeated cross-sectional analysis included adults aged 18 years or older who completed the All of Us Lifestyle Survey between 2017 and 2023. Current and daily e-cigarette use were ascertained through self-reported survey items. The analytic cohort was sex-balanced through random subsampling of female participants (1:1 ratio), and overall prevalence estimates were age-standardized to the 2020 U.S. Census adult age distribution. All analyses were descriptive. Results: The analytic sample included 418,772 participants. Age-standardized prevalence of current e-cigarette use was 6.1% (95% CI: 6.0–6.2), and daily use was 2.4% (95% CI: 2.3–2.4). Prevalence was highest among adults aged 18–24 years (13.3%), male participants (7.0%), and those with depression (7.5%). Annual current use prevalence rose from 3.8% in 2017 to 8.5% in 2023, with a dip to 4.5% in 2020. Among young adults reporting current e-cigarette use, the proportion reporting never combustible cigarette use grew from 51.5% in 2017 to 65.2% in 2023. Conclusions: E-cigarette use was most common among young adults, with patterns consistent with nationally representative datasets. These findings support the potential of the All of Us Research Program as a complementary resource for monitoring e-cigarette use.

  • Open Access

    The U.S. Mortality Crisis as a Preston Curve Reversal

    by Ritikaa Khanna, Rourke O&Apos;Brien, Andrew C. Stokes, Atheendar Venkataramani, Elizabeth Wrigley-Field

    U.S. life expectancy stagnated and declined in the 2010s despite continued growth in real per capita income. We use Preston curves to characterize this pattern as a change in the relationship between income and longevity. Using state-level data from 1980 to 2019 and county-level data from 2000 to 2019, we estimate population-weighted Preston curves relating life expectancy to logged real per capita income. From 1980 to 2010, U.S. states followed the classic Preston curve pattern: rising income was accompanied by rising life expectancy. Counties followed the same pattern from 2000 to 2010. From 2010 to 2019, however, states and counties continued to become richer while life expectancy stagnated or declined. The curves shifted right without shifting up and became steeper, indicating decoupling and divergence: increases in aggregate resources over time no longer produced broad longevity gains, and, in any given year, inequality in life expectancy by income grew. These patterns are robust to alternative temporal anchors around the Great Recession and to substituting education for income. They also appear across sex and racial groups. County-level decompositions are broadly consistent with arguments that longevity has fallen due to widely shared exposures to social deterioration, which may account for the Preston curve reversal. Collectively, we show that the recent U.S. mortality crisis reveals a weakening—and growing inequality—in the conversion of aggregate resources into longevity gains. We conclude that the recent U.S. mortality crisis could be understood not only as a story about particular causes of death, but also as a weakening of institutional and social translation.Institutional subscribers to the NBER working paper series, and residents of developing countries may download this paper without additional charge at www.nber.org.

  • Top Cited Papers
    Open Access

    Applying machine learning to identify unrecognized COVID-19 deaths recorded as other causes of death in the United States

    by Mathew V. Kiang, Zehang Richard Li, Elizabeth Wrigley-Field, Rafeya V. Raquib, Dielle J. Lundberg, Eugenio Paglino, Benjamin Huynh, Kirsten Bibbins-Domingo, M. Maria Glymour, Andrew C. Stokes

    The actual number of US deaths caused by severe acute respiratory syndrome coronavirus 2 infection has been investigated and debated since the start of the COVID-19 pandemic. Here, we use machine learning trained on US death certificates from March 2020 to December 2021 to predict 155,536 (95% uncertainty interval: 150,062 to 161,112) unrecognized COVID-19 deaths. This indicates that 19% more COVID-19 deaths occurred in the US than officially reported. Predicted unrecognized COVID-19 deaths occurred disproportionately among decedents with less than a high school education; decedents identified as Hispanic, American Indian, Alaska Native, Asian, and/or Black; counties with lower household incomes and worse preexisting health; and counties in the South. These findings suggest that the US death investigation system undercounted COVID-19 deaths unevenly, hiding the true extent of inequities.


  • Open Access

    Quantifying the Dementia Burden Attributable to Excess Weight in the U.S.

    by Jordan Weiss, Meghan I. Podolsky, Rafeya V. Raquib, Phillip Hwang, Andrew C. Stokes


  • Excess Deaths Attributable to the Los Angeles Wildfires From January 5 to February 1, 2025

    by Eugenio Paglino, Rafeya V. Raquib, Andrew C. Stokes

    This study aims to estimate the number of excess deaths attributable to the Los Angeles wildfires using an interrupted time series design.


  • Open Access

    National evidence on glucose-lowering medication use for diabetes from 62 low- and middle-income countries

    by Felix Teufel, Pia Roddewig, Maja E. Marcus, Michaela Theilmann, Glennis Andall-Brereton, Krishna Aryal, Sina Azadnajafabad, Pascal Bovet, Maria Dorobantu, Farshad Farzadfar, et al.

    Given rising diabetes prevalence globally, access to diabetes treatments is gaining urgency. Yet, it remains unknown which glucose-lowering medication types people with diabetes across low- and middle-income countries (LMICs) use. In this cross-sectional analysis, we pooled nationally representative data of 223,283 adults aged ≥25 years in 62 LMICs from 2009 to 2019. We found that 51.9% [95%-CI: 49.6%, 54.2%] of 21,715 individuals with diabetes were undiagnosed. Among individuals with diagnosed diabetes, 18.6% [95%-CI: 14.5%, 23.4%] reported using no glucose-lowering medication, 57.3% [95%-CI: 53.1%, 61.4%] only used oral medication, 19.5% [95%-CI: 17.6%, 21.5%] used oral medication and insulin, and 4.7% [95%-CI: 3.9%, 5.6%] used insulin alone. In low-income countries, fewer individuals with diabetes were diagnosed and treated than in middle-income countries. Yet, among individuals who did get diagnosed, insulin use was two-thirds higher in low-income countries (38.9% [95%-CI: 31.6%, 46.7%]) compared to middle-income countries (23.2%; 95%-CI: 21.0%, 25.5%]). This finding could suggest a need for earlier diagnosis and treatment initiation. Our results can inform national and regional drug procurement efforts across LMICs.


  • Sociodemographic, health-related, and clinical characteristics and their associations with mortality among All of Us participants compared with the United States general population

    by Jingxuan Wang, Erin L Ferguson, Peter Buto, Ruijia Chen, Anna Pederson, Minhyuk Choi, Andrew C Stokes, Deborah Blacker, M Maria Glymour

    The large and diverse All of Us Research Program offers tremendous opportunities for health research. However, results may not be generalizable to the US population due to the program’s targeted recruitment efforts. We compared All of Us participants to those from the nationally representative continuous 1999-2018 National Health and Nutrition Examination Survey (NHANES) with respect to overall mortality rates; the distribution of sociodemographic, health-related, and clinical characteristics; the association of each characteristic with mortality estimated using Cox proportional hazards models; and population attributable fractions (PAFs) for each characteristic and mortality. All of Us participants were older, less likely to be non-Hispanic White, had more years of education, and had a higher prevalence of major chronic conditions than NHANES. Mortality rates were generally lower for All of Us participants, especially at older ages. The direction of associations in All of Us and NHANES matched for almost all comparisons but differed in magnitude for some conditions, primarily clinical diagnoses. PAFs were generally higher in All of Us. Predictors of mortality in All of Us do not consistently generalize to the US population. Analytical approaches are needed to address nonrepresentativeness and mitigate potential biases associated with the selection into the All of Us cohort.


  • Open Access

    Diverging Mortality Trends by Educational Attainment in the US

    by Eugenio Paglino, Elizabeth Wrigley-Field, Andrew C. Stokes

    This cross-sectional study examines trends in US mortality rates by sex and educational attainment before, during, and after the COVID-19 pandemic.


  • Open Access

    Evolution of the US nonmetropolitan mortality disadvantage by sex, state, and year, 1999‐2019

    by Eugenio Paglino, Irma T. Elo, Samuel H. Preston, Katherine Hempstead, Andrew C. Stokes

    Purpose: To examine disparities in nonmetropolitan and metropolitan mortality by state and sex from 1999 to 2019.Methods: We calculate age‐standardized mortality rates for nonmetropolitan and metropolitan areas by state and sex and compute age‐standardized differences in these rates within each state and relative to the national average. We further estimate the number of excess deaths in nonmetropolitan areas by state. These are deaths that would have been avoided if nonmetropolitan areas had the same age‐specific death rates as metropolitan areas in the same state.Findings: We document increasing nonmetropolitan mortality disadvantage since 1999 along with significant variation in the magnitude and timing of its emergence by state. Although stagnation in mortality was observed nationally in the mid‐2010s, this was not true in all states or in all metropolitan and nonmetropolitan areas. Additionally, mortality trends became progressively more discordant across and within states. Despite this heterogeneity, we document a steady increase in the number of nonmetropolitan excess deaths from 8,400 in 1999 to 47,000 in 2019, representing 9.0% of all nonmetropolitan deaths.Conclusions: National‐level mortality trends mask geographic variation by nonmetropolitan and metropolitan areas within and across states. Further research is needed to identify factors that contribute to these divergent patterns.